Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

Weekly Roundup – May 26, 2022 

View this email in your browser Weekly Roundup – May 26, 2022                          Welcome...

| By Caitlin Truesdale

Pfizer pledges to provide not-for-profit medicines

Pfizer has committed to providing all its current and future patent-protected medicines on a not-for-profit basis to 45 lower-income countries. Albert Bourla, Chief Executive Officer at Pfizer,...

| By Caitlin Truesdale

Taconic expands production site in Indiana

Taconic Biosciences has broken ground on a new production facility, expanding the footprint at its 27.9-acre Cambridge City, IN, campus. Taconic is a fully-licensed, global leader in...

| By Caitlin Truesdale

Career News – May 24, 2022 

View this email in your browser Career News – May 24, 2022                          BioCT company...

| By Caitlin Truesdale

Rallybio acquires anemia candidate from Sanofi

Rallybio, a New Haven biotech, has acquired from Sanofi worldwide exclusive rights to develop a drug candidate designed to treat patients with severe anemia from...

| By Caitlin Truesdale

BioCT welcomes new member Nucleate

Nucleate is a collaborative student-run organization that facilitates the formation of pioneering life sciences companies. It is a non-profit organization that educates and empowers the next generation...

| By Caitlin Truesdale

Honors, promotions recognize CT bioscience talent

Craig M. Crews, the John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, Pharmacology, and Management at Yale University, together with...

| By Caitlin Truesdale

Weekly Roundup – May 19, 2022 

View this email in your browser Weekly Roundup – May 19, 2022                           AdvanceCT recently published the...

| By Caitlin Truesdale

Yale Innovation Summit notes thriving CT sector

With global markets continuing to slide, expect valuations to shrink and capital raises to get more difficult for the New Haven area’s bioscience companies, a...

| By Caitlin Truesdale

Bioasis and Neuramedy in license agreement

Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement...